当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.

Abstract：

PURPOSE:There is as yet no optimal treatment regimen for patients with epidermal growth factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has progressed despite cytotoxic chemotherapy. This trial was performed to evaluate the efficacy and toxicity of erlotinib, a tyrosine kinase inhibitor of EGFR, in Japanese patients with EGFR wild-type tumors. METHODS:Patients with stage III/IV or postoperative recurrence of NSCLC whose tumors have wild-type EGFR were eligible. Erlotinib (150 mg/day) was administered until disease progression or unacceptable toxicity occurred. The primary end point was disease control rate (DCR). RESULTS:Thirty-one patients (23 men and 8 women; median age, 71 years; range, 31-89) were enrolled between January 2008 and June 2011. Twenty-one had adenocarcinoma, nine had squamous cell carcinoma, and one had large cell carcinoma. Ten, nine, eight, and four patients showed performance status 0, 1, 2, and 3, respectively. Erlotinib was administered following the median 3.1 regimens of cytotoxic chemotherapies. One patient achieved complete response, four showed partial response, and eight had stable disease. Thus, response rate was 17.2%, and DCR was 44.8%. Skin rash was the most common side effect (80.6%). Two patients developed interstitial lung disease. Nevertheless, all of these events were reversible, and there were no treatment-related deaths. The median progression-free survival and survival times were 2.1 and 7.7 months, respectively. CONCLUSION:Erlotinib might be an alternative option for patients resistant to cytotoxic chemotherapy even in those with EGFR wild-type NSCLC.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Kobayashi T,Koizumi T,Agatsuma T,Yasuo M,Tsushima K,Kubo K,Eda S,Kuraishi H,Koyama S,Hachiya T,Ohura N

doi

10.1007/s00280-012-1831-0

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

1241-6

issue

5

eissn

0344-5704

issn

1432-0843

journal_volume

69

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.

    abstract：:Brain microdialysis was applied to sample free methotrexate (MTX) concentrations in brain extracellular fluid of normal and RG-2 glioma-bearing rats. All animals received 50 mg/kg of MTX intra-arterially following which serial blood and interstitial fluid samples were collected for 3 h and measured for MTX by an HPLC ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050518

    authors： Devineni D,Klein-Szanto A,Gallo JM

    更新日期：1996-01-01 00:00:00

  • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.

    abstract：OBJECTIVE:Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in brea...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-020-04030-2

    authors： Pothuri B,Brodsky AL,Sparano JA,Blank SV,Kim M,Hershman DL,Tiersten A,Kiesel BF,Beumer JH,Liebes L,Muggia F

    更新日期：2020-04-01 00:00:00

  • Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.

    abstract：:A total of 40 patients with recurrent non-Hodgkin's lymphoma were treated with ABEP combination chemotherapy (aclarubicin, N4-behenoyl-1-beta-D-arabinofuranosylcytosine, etoposide, and prednisolone). A complete remission (CR) was achieved in 37.5% of the patients and partial remission, in 15.0%. The ABEP regimen prove...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00692354

    authors： Yoshida T,Nakamura S,Ohtake S,Kobayashi K,Kanno M,Matsuda T,Matano S,Kondo K,Okafuji K,Kanai M

    更新日期：1989-01-01 00:00:00

  • Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats.

    abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00256721

    authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

    更新日期：1983-01-01 00:00:00

  • Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

    abstract：:We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0554-0

    authors： Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

    更新日期：2008-05-01 00:00:00

  • Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

    abstract：PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1498-3

    authors： Waud WR,Gilbert KS,Secrist JA 3rd

    更新日期：2011-08-01 00:00:00

  • Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

    abstract：:All-trans-retinoic acid (ATRA) has been incorporated in front-line therapy for newly diagnosed acute promyelocytic leukemia (APL). We conducted a multicenter study of differentiation therapy with ATRA alone or in combination with chemotherapy followed by intensive postremission chemotherapy in patients with APL (the J...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s002800100308

    authors： Asou N,Adachi K,Tamura U,Kanamaru A,Kageyama S,Hiraoka A,Omoto E,Akiyama H,Tsubaki K,Saito K,Kuriyama K,Oh H,Kitano K,Miyawaki S,Takeyama U,Yamada O,Nishikawa K,Takahashi M,Matsuda S,Ohtake H,Ohno R

    更新日期：2001-08-01 00:00:00

  • High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

    abstract：:Nine children with poor-prognosis malignancies--seven with advanced neuroblastoma and two with metastatic Ewing's sarcoma--were given high doses of melphalan (HDM), 150 mg/m2 (3 patients) and 180 mg/m2 (6 patients), as a 'late intensification' agent combined with noncryopreserved autologous bone marrow transplants. Me...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00263898

    authors： Ninane J,Baurain R,de Selys A,Trouet A,Cornu G

    更新日期：1985-01-01 00:00:00

  • A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

    abstract：PURPOSE:The artemisinin class of anti-malarial drugs has shown significant anti-cancer activity in pre-clinical models. Proposed anti-cancer mechanisms include DNA damage, inhibition of angiogenesis, TRAIL-mediated apoptosis, and inhibition of signaling pathways. We performed a phase I study to determine the maximum to...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3533-8

    authors： Deeken JF,Wang H,Hartley M,Cheema AK,Smaglo B,Hwang JJ,He AR,Weiner LM,Marshall JL,Giaccone G,Liu S,Luecht J,Spiegel JY,Pishvaian MJ

    更新日期：2018-03-01 00:00:00

  • Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.

    abstract：:Doxifluridine (5'-deoxy-5-fluorouridine, 5'-dFUR) metabolism has been reported to be saturable and associated with a fall in clearance of the drug as the dose is increased. The aim of the present study was to determine the disposition of 5'-dFUR and 5-fluorouracil (5-FU) when 5'-dFUR was given as a 5-day infusion, wit...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00684885

    authors： Reece PA,Olver IN,Morris RG,Bishop JF,Guentert TW,Hill HS,Hillcoat BL

    更新日期：1990-01-01 00:00:00

  • Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.

    abstract：:Twenty-seven patients with liver metastases from colorectal carcinoma were treated with 5-fluorouracil, adriamycin, and mitomycin C (FAM) by hepatic artery infusion (HAI) every 2-3 months for a maximum of eight courses. Median survival for all patients was 22 months. Toxicity was acceptable and consisted in severe mye...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00269032

    authors： Wils J,Schlangen J,Naus A

    更新日期：1984-01-01 00:00:00

  • Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.

    abstract：:The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28-72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686315

    authors： Bressolle F,Jacquet JM,Galtier M,Jourdan J,Donadio D,Rossi JF

    更新日期：1992-01-01 00:00:00

  • Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

    abstract：:Pyrazine diazohydroxide (sodium salt, NSC 361456; PZDH) is a new antitumor drug with relatively broad activity in initial evaluations against murine leukemias, solid tumors, and two human tumor xenografts in vivo. The present studies were designed to address questions about PZDH activity on different treatment schedul...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686053

    authors： Harrison SD Jr,Plowman J,Dykes DJ,Waud WR,Griswold DP Jr

    更新日期：1990-01-01 00:00:00

  • Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.

    abstract：PURPOSE:Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-kappaB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with advanced solid malignancies. PATIENTS-METHODS:Initially, patients received MM...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0826-3

    authors： Xu Y,Kolesar JM,Schaaf LJ,Drengler R,Duan W,Otterson G,Shapiro C,Kuhn J,Villalona-Calero MA

    更新日期：2009-05-01 00:00:00

  • Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice.

    abstract：PURPOSE:The aim of this study was to investigate the relationship between changes in IL-1β expression and intestinal apoptosis after chemotherapy. And we further determine whether interleukin-1 receptor antagonist (IL-1Ra) reduces apoptosis in vivo after 5-fluorouracil (5-FU) chemotherapy in the small intestine. METHO...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1451-5

    authors： Wu ZQ,Han XD,Wang Y,Yuan KL,Jin ZM,Di JZ,Yan J,Pan Y,Zhang P,Huang XY,Wang ZG,Zheng Q

    更新日期：2011-07-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.

    abstract：PURPOSE:To evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in a nonhuman primate model. METHODS:Tasidotin 0.75 mg/kg was administered intravenously. The plasma and CSF concentrations of tasidotin and its metabolites were determined. Pharmacokinetic pa...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0875-7

    authors： Kilburn LB,Bonate PL,Blaney SM,McGuffey L,Nuchtern JG,Dauser R,Thompson P,Gibson BW,Berg SL

    更新日期：2009-07-01 00:00:00

  • Initial clinical experience with a simultaneous combination of 2,4-diamino-5(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) with folinic acid.

    abstract：:DDMP, a diaminopyrimidine folate antagonist, was given to 26 tumor patients in a dosage of 50 mg/m2 per week orally, simultaneously with 3 mg CF i.m. or i.v. The CF dose was increased to 30 mg in patients showing evidence of toxicity, and withdrawn in the absence of toxicity. The dose-limiting toxicity was seen in mye...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00254043

    authors： Alberto P,Peytremann R,Medenica R,Beretta-Piccoli M

    更新日期：1978-01-01 00:00:00

  • A clinical study of nafazatrom in advanced human breast cancer.

    abstract：:Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objectiv...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00685120

    authors： Jones AL,Powles TJ,Forgeson GV,Coombes RC

    更新日期：1991-01-01 00:00:00

  • Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

    abstract：PURPOSE:Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active metabolite 9-aminocamptothecin (9-AC) for use in phase II/III studies with oral rubitecan administered in a daily times five schedule. METHODS:Concentration-time data of rubitecan and 9-A...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-002-0516-5

    authors： Schoemaker NE,Mathôt RA,Schöffski P,Rosing H,Schellens JH,Beijnen JH

    更新日期：2002-12-01 00:00:00

  • Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.

    abstract：PURPOSE:This phase I study was undertaken to evaluate the safety and tolerability of prolonged infusional etoposide, and to evaluate its pharmacokinetic/pharmacodynamic profile in patients with advanced cancer. METHODS:A group of 17 patients received a 7-day infusion of etoposide (schedule A) every 21 days at doses fr...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050511

    authors： Robert F,Chen S,Miller AA,Lee BC,Molthrop DC,Wheeler RH

    更新日期：1996-01-01 00:00:00

  • Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

    abstract：PURPOSE:This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. METHODS:Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methot...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-0954-4

    authors： Izbicka E,Diaz A,Streeper R,Wick M,Campos D,Steffen R,Saunders M

    更新日期：2009-10-01 00:00:00

  • High-dose dexamethasone for prevention of cis-platin-induced vomiting.

    abstract：:Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00258206

    authors： Aapro MS,Alberts DS

    更新日期：1981-01-01 00:00:00

  • In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model.

    abstract：:Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, usi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0917-8

    authors： Ye CL,Liu JW,Wei DZ,Lu YH,Qian F

    更新日期：2005-05-01 00:00:00

  • Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.

    abstract：:We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N',N"-triethylenethiophosphoramide (thiotepa). The cell lines studied in...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00299860

    authors： Seidenfeld J,Komar KA,Naujokas MF,Block AL

    更新日期：1986-01-01 00:00:00

  • Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

    abstract：:Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689280

    authors： Pujol JL,Cupissol D,Gestin-Boyer C,Bres J,Serrou B,Michel FB

    更新日期：1990-01-01 00:00:00

  • Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.

    abstract：PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3067-x

    authors： Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

    更新日期：2016-07-01 00:00:00

  • Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines.

    abstract：PURPOSE:Nephrotoxicity is one of the major dose-limiting side-effects of cisplatin (DDP). The disproportionate accumulation of cisplatin in kidney tissue may play an important role, however, therapeutic measures to prevent this prime cause of nephrotoxicity are not available. Because certain amino acids (AAs) have been...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/PL00006741

    authors： Kröning R,Lichtenstein AK,Nagami GT

    更新日期：2000-01-01 00:00:00

  • Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.

    abstract：PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in pl...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0437-4

    authors： Cummings J,Ranson M,Butt F,Moore D,Dive C

    更新日期：2007-11-01 00:00:00

  • Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.

    abstract：PURPOSE:Although oral fluoropyrimidine prodrugs are increasingly being administered in preference to intravenous nucleoside analogues in cancer chemotherapy, their activation in malignant liver tissue may be insufficient. OGT 719 (1-galactopyranosyl-5-fluorouracil) is a novel nucleoside analogue, preferentially localiz...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800100332

    authors： Sharma RA,Eatock MM,Twelves CJ,Brown G,McLelland HR,Clayton KT,O'Byrne KJ,Moyses C,Carmichael J,Steward WP

    更新日期：2001-09-01 00:00:00

  • D-dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE.

    abstract：PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03778-6

    authors： Chen X,Chang Z,Liu Z

    更新日期：2019-04-01 00:00:00